Assay development, compound screening, and disease-relevant profiling that ground drug discovery in real biology — turning targets and libraries into validated, de-risked starting points for development.
"Discovery grounded in disease-relevant biology, ready to advance."
Great programmes are made or lost in the pre-clinical stage. We develop the assays, run the screens, and profile the hits that ground discovery in disease-relevant biology — so the compounds that advance are the ones most likely to succeed.
From target-based and phenotypic assays to complex disease models, our work turns libraries and targets into validated, prioritised starting points for the clinic.
Miniaturized, target-based assays for major protein classes plus complex cell-based systems — optical, label-free, and high-content imaging (Cell-Painting).
Screening against small molecule libraries or focused subsets — including natural-product and drug-repurposing collections — on high-throughput infrastructure.
2D and 3D cultures, patient-derived cells, and organoids that ground discovery in the biology that matters for translation.
Prioritise hits by mechanism-of-action, selectivity, and ADMET profiling, supported by robust informatics.
Progress validated hits to industry-standard Lead and clinical Candidate milestones along a clear critical path.
Early translational readiness — building the evidence that de-risks a compound before it reaches the clinic.
Grounded in real drug-screening and compound-repurposing practice: target- and cell-based assays, access to compound libraries, high-content imaging, and integrated high-throughput screening hardware — with a track record across repurposing, rare disease, and oncology.
Diverse screening compounds and repurposing collections
Target- and cell-based, disease-relevant assay systems
Proven progression along drug-discovery critical paths
Discovery data becomes far more powerful when it is digitised as FAIR data and reasoned over by the AI layer — turning every screen and assay into reusable, decision-ready knowledge.
Lab Digitisation — capture discovery data as structured, FAIR records.
AI — reason across screening data to predict and prioritise.
We'll design the assay, run the screen, and profile the hits — delivering validated, de-risked starting points for discovery.
Discuss a programme →